Active Biotech AB Interim report January - September 2015
(Thomson Reuters ONE) -
Laquinimod
* The pivotal CONCERTO clinical Phase 3 study in relapsing remitting MS (RRMS)
is proceeding according to plan and results are expected in 2017
* The Phase 2 studies, ARPEGGIO, which will evaluate laquinimod's potential
for treatment of primary progressive MS (PPMS), and LEGATO-HD, for the
treatment of Huntington's disease, are proceeding as planned
Tasquinimod
* The final results from Active Biotech's tasquinimod 10TASQ10 Phase 3 trial
were presented at the ECC conference and demonstrated that while tasquinimod
treatment resulted in a prolonged radiographic progression-free survival
(rPFS), 7.0 vs. 4.4 months, the positive effect on rPFS did not translate
into an improved OS
ISI
* Only commercial activities will be conducted from 2016
Financial summary
MSEK July - Sept. Jan. - Sept. Jan. - Dec.
2015 2014 2015 2014 2014
-------------------------------------------------------------------------------
Net sales 5.2 2.6 11.3 7.5 10.4
Operating loss -22.2 -55.7 -149.7 -172.8 -228.5
Loss for the period -23.4 -56.6 -152.7 -174.5 -231.5
Loss per share, before and after -0.26 -0.76 -1.70 -2.33 -3.02
dilution (SEK)
Cash and cash equivalents (at 132.4 161.0 328.5
the end of the period)
For further information, please contact:
Tomas Leanderson, Active Biotech AB
President and CEO (Corp. Reg. No. 556223-9227)
Tel: +46 (0)46 19 20 95 Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00
Hans Kolam, CFO Fax: +46 (0)46 19 11 00
Tel: +46 (0)46 19 20 44
The report is also available at www.activebiotech.com.
Active Biotech AB Interim report January - September 2015:
http://hugin.info/1002/R/1964749/717166.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Active Biotech via GlobeNewswire
[HUG#1964749]
Unternehmensinformation / Kurzprofil:
Datum: 06.11.2015 - 08:30 Uhr
Sprache: Deutsch
News-ID 432518
Anzahl Zeichen: 2934
contact information:
Town:
LUND
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 187 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Active Biotech AB Interim report January - September 2015"
steht unter der journalistisch-redaktionellen Verantwortung von
Active Biotech (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
